# CAPTIVATE (NCT02910583)

> Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)

No report yet. It can be ordered.

- Drugs tested: ibrutinib plus venetoclax
- Indication: treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02910583
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Pharmacyclics LLC.
- Conditions: Leukemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
- Interventions: ibrutinib; venetoclax; Placebo
- Enrollment: 323
- Primary outcome: MRD Cohort: 1-Year Disease-Free Survival (DFS) Rate in Confirmed uMRD Randomized Participants
- Primary outcome: FD Cohort: Complete Response Rate (CRR; Complete Response/Complete Response With Incomplete Blood Count Recovery [CR/CRi]) Rate

## Questions raised in the commentary

_Automated from the 40 newest of 233 indexed sources (Oct 2025 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether the original regimen can be reused after relapse following fixed-duration therapy
- Whether treatment duration should differ for high-risk disease
- How MRD should guide treatment duration, including whether to stop at undetectable MRD

Also discussed: resistance mutations, IGHV status.

## Indexed commentary on CAPTIVATE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 117
- Podcasts: 72
- X threads: 43
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=captivate-nct02910583

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02910583", "email": "<work email>"}; the inbox owner confirms by the emailed link.